AU2002315658A1 - Buffer solution for electroporation and a method comprising the use of the same - Google Patents

Buffer solution for electroporation and a method comprising the use of the same

Info

Publication number: AU2002315658A1
Authority: AU; Australia
Prior art keywords: electroporation; same; buffer solution; buffer; solution
Prior art date: 2001-04-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

AU2002315658A

Other versions

AU2002315658B2 (en

Inventor

Helmut Brosterhus

Juliana Helfrich

Elke Lorbach

Herbert Muller-Hartmann

Michael Nix

Gudula Riemen

Kirsten Rothmann

Gregor Siebenkotten

Corinna Thiel

Meike Weigel

Heike Wessendorf

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Lonza Cologne GmbH

Original Assignee

Lonza Cologne GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-23

Filing date

2002-04-23

Publication date

2003-04-17

2002-04-23 Application filed by Lonza Cologne GmbH filed Critical Lonza Cologne GmbH

2002-04-23 Priority claimed from PCT/DE2002/001483 external-priority patent/WO2002086134A2/en

2003-04-17 Publication of AU2002315658A1 publication Critical patent/AU2002315658A1/en

2007-02-08 Application granted granted Critical

2007-02-08 Publication of AU2002315658B2 publication Critical patent/AU2002315658B2/en

2007-05-08 Priority to AU2007202057A priority Critical patent/AU2007202057B2/en

2007-11-22 Assigned to AMAXA AKTIENGESELLSCHAFT reassignment AMAXA AKTIENGESELLSCHAFT Request for Assignment Assignors: AMAXA GMBH

2009-12-10 Assigned to LONZA COLOGNE AG reassignment LONZA COLOGNE AG Request to Amend Deed and Register Assignors: AMAXA AKTIENGESELLSCHAFT

2011-06-02 Assigned to LONZA COLOGNE GMBH reassignment LONZA COLOGNE GMBH Request to Amend Deed and Register Assignors: LONZA COLOGNE AG

2022-04-23 Anticipated expiration legal-status Critical

Status Expired legal-status Critical Current

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2007202057A AU2007202057B2 (en)	2001-04-23	2007-05-08	Buffer solution for electroporation

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10120000.5		2001-04-23
DE10120000		2001-04-23
PCT/DE2002/001483 WO2002086134A2 (en)	2001-04-23	2002-04-23	Buffer solution for electroporation and a method comprising the use of the same

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2007202057A Division AU2007202057B2 (en)	2001-04-23	2007-05-08	Buffer solution for electroporation

Publications (2)

Publication Number	Publication Date
AU2002315658A1 true AU2002315658A1 (en)	2003-04-17
AU2002315658B2 AU2002315658B2 (en)	2007-02-08

Family

ID=7682502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002315658A Expired AU2002315658B2 (en)	2001-04-23	2002-04-23	Buffer solution for electroporation and a method comprising the use of the same

Country Status (15)

Country	Link
US (5)	US7332332B2 (en)
EP (1)	EP1390518B1 (en)
JP (1)	JP4070611B2 (en)
KR (2)	KR100845057B1 (en)
CN (1)	CN1302115C (en)
AT (1)	ATE278796T1 (en)
AU (1)	AU2002315658B2 (en)
CA (1)	CA2445260C (en)
DE (2)	DE10291734D2 (en)
ES (1)	ES2230502T3 (en)
IL (1)	IL158514A0 (en)
MX (1)	MXPA03009622A (en)
NO (1)	NO20034682L (en)
WO (1)	WO2002086134A2 (en)
ZA (1)	ZA200308127B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1369108A4 (en) *	2001-02-19	2007-06-20	Pola Chem Ind Inc	Composition for use in electroporation
DE10291734D2 (en) *	2001-04-23	2004-05-27	Lorbach Elke	Buffer solution for electroporation and methods comprising using the same
CA2457959C (en) *	2001-06-05	2014-10-28	Curevac Gmbh	Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
DE10162480A1 (en)	2001-12-19	2003-08-07	Ingmar Hoerr	The application of mRNA for use as a therapeutic agent against tumor diseases
DE102004042546A1 (en) *	2004-09-02	2006-03-09	Curevac Gmbh	Combination therapy for immune stimulation
DE102005023170A1 (en) *	2005-05-19	2006-11-23	Curevac Gmbh	Optimized formulation for mRNA
DE502005002350D1 (en) *	2005-07-07	2008-02-07	Amaxa Ag	Method for treating small volumes with electric current
DE102005035456A1 (en) *	2005-07-28	2007-03-08	Eppendorf Ag	A method of electromanipulating cells to alter the membrane permeability of these cells using lipophilic ions as a medium supplement
US8278104B2 (en)	2005-12-13	2012-10-02	Kyoto University	Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8129187B2 (en)	2005-12-13	2012-03-06	Kyoto University	Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
MX352337B (en)	2005-12-13	2017-11-21	Univ Kyoto	Nuclear reprogramming factor.
US20090142805A1 (en) *	2007-01-08	2009-06-04	Millipore Corporation	High expression cell line that eliminates gene amplification
US20080268542A1 (en) *	2007-04-30	2008-10-30	Bio-Rad Laboratories, Inc.	High Efficiency Electroporation Buffer
JP2008307007A (en)	2007-06-15	2008-12-25	Bayer Schering Pharma Ag	Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US9213999B2 (en)	2007-06-15	2015-12-15	Kyoto University	Providing iPSCs to a customer
CA2695522C (en)	2008-05-02	2019-01-15	Kyoto University	Method of nuclear reprogramming
EP2600901B1 (en)	2010-08-06	2019-03-27	ModernaTX, Inc.	A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP2857499A1 (en)	2010-10-01	2015-04-08	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
WO2012051599A2 (en)	2010-10-15	2012-04-19	Eos Neuroscience, Inc.	Modulation neural pathways
WO2012082688A1 (en)	2010-12-15	2012-06-21	Old Dominion University Research Foundation	Electroporation-induced electrosensitization
WO2012098260A1 (en)	2011-01-21	2012-07-26	Axiogenesis Ag	A non-viral system for the generation of induced pluripotent stem (ips) cells
CA2831613A1 (en)	2011-03-31	2012-10-04	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
HUE057725T2 (en)	2011-10-03	2022-06-28	Modernatx Inc	Modified nucleosides, nucleotides and nucleic acids and their uses
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
EP3505176A1 (en)	2012-04-02	2019-07-03	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of secreted proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
KR101923632B1 (en)	2012-07-31	2018-12-03	이스케이프 테라퓨틱스, 인코퍼레이티드	Hla g-modified cells and methods
BR112015002268A2 (en)	2012-08-03	2017-11-07	Sanofi Pasteur	production of infectious influenza viruses
PL2922554T3 (en)	2012-11-26	2022-06-20	Modernatx, Inc.	Terminally modified rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US9493742B2 (en)	2013-03-15	2016-11-15	Emory University	Purification of cell mixtures using molecular beacons targeting cell specific RNA
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
WO2015062738A1 (en)	2013-11-01	2015-05-07	Curevac Gmbh	Modified rna with decreased immunostimulatory properties
EP3250693B2 (en)	2015-01-30	2023-12-20	The Regents of The University of California	Protein delivery in primary hematopoietic cells
US10093706B2 (en)	2017-01-30	2018-10-09	Indiana University Research And Technology Corporation	Dominant positive hnRNP-E1 polypeptide compositions and methods
BR112020008201A2 (en)	2017-10-27	2020-10-06	The Regents Of The University Of California	target replacement of endogenous t cell receptors
WO2020014235A1 (en)	2018-07-09	2020-01-16	The Regents Of The University Of California	Gene targets for t-cell-based immunotherapy
US20220282282A1 (en) *	2021-02-26	2022-09-08	Precigen, Inc.	Buffer solutions for electroporation
WO2023001156A1 (en) *	2021-07-19	2023-01-26	Wuhan University	Compositions and methods for effective delivery of polynucleotides to cells
KR20240099259A (en)	2021-10-14	2024-06-28	아스널 바이오사이언시스, 인크.	Immune cells with co-expressed SHRNA and logic gate system
EP4279085A1 (en)	2022-05-20	2023-11-22	Mnemo Therapeutics	Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024059618A2 (en)	2022-09-13	2024-03-21	Arsenal Biosciences, Inc.	Immune cells having co-expressed tgfbr shrnas
CN115386598A (en) *	2022-09-16	2022-11-25	南京艾尔普再生医学科技有限公司	Immune cell electrotransformation liquid and preparation method thereof
WO2024059824A2 (en)	2022-09-16	2024-03-21	Arsenal Biosciences, Inc.	Immune cells with combination gene perturbations
TW202442689A (en)	2023-03-03	2024-11-01	美商亞森諾生物科學公司	Systems targeting psma and ca9
TW202436346A (en)	2023-03-13	2024-09-16	美商亞森諾生物科學公司	Synthetic pathway activators
WO2024226827A2 (en)	2023-04-25	2024-10-31	Arsenal Biosciences, Inc.	Novel receptors for transcription regulation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US34256A (en) *		1862-01-28		Improvement in grading and excavating machines
US829633A (en) *	1905-11-11	1906-08-28	Harry R Decker	Drill.
US2109108A (en)	1935-08-19	1938-02-22	Douglas F Fesler	Knife
US6048729A (en) *	1987-05-01	2000-04-11	Transkaryotic Therapies, Inc.	In vivo protein production and delivery system for gene therapy
SE457935B (en)	1987-07-08	1989-02-13	Seco Tools Ab	TOOLS FOR CUTTING PROCESSING AND CUTTING BEFORE TOOLS
USRE34256E (en)	1987-07-08	1993-05-18	Seco Tools Ab	Tool for metal cutting
US4964762A (en)	1987-09-18	1990-10-23	Mitsubishi Kinzoku Kabushiki Kaisha	Combination of cutter and fastener unit therefor
US5124259A (en) *	1989-08-23	1992-06-23	Mitsui Toatsu Chemicals, Inc.	Method for electroporation
BE1004328A3 (en) *	1990-05-16	1992-11-03	Scient Equipment Design & Dev	METHOD AND DEVICE FOR LIVING CELLS permeabilization.
CA2066374C (en) *	1991-04-19	2002-01-29	Paul E. Segall	Solution for perfusing primates
US5329028A (en) *	1992-08-05	1994-07-12	Genentech, Inc.	Carbohydrate-directed cross-linking reagents
JPH07502544A (en) *	1992-10-21	1995-03-16	アルコン　ラボラトリーズ，インコーポレイテッド	Composition for intraocular tissue irrigation and for maintaining pupil dilation during intraocular surgical procedures
GB9317380D0 (en) *	1993-08-20	1993-10-06	Therexsys Ltd	Transfection process
US5498531A (en) *	1993-09-10	1996-03-12	President And Fellows Of Harvard College	Intron-mediated recombinant techniques and reagents
WO1995035389A1 (en)	1994-06-17	1995-12-28	Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno	Method for introduction of genetic material into microorganisms and transformants obtained therewith
WO1997041242A1 (en) *	1996-04-18	1997-11-06	Geron Corporation	Senescence responsive transcriptional element
WO1997042951A1 (en) *	1996-05-16	1997-11-20	Board Of Regents, The University Of Texas System	Methods of identifying modulators of perivascular sensory nerve ca2+ receptors
SE509931C2 (en)	1996-09-27	1999-03-22	Seco Tools Ab	Swivel mill, swivel head and method of mounting a removable swivel head on a shaft for a swivel
US20030065039A1 (en) *	1997-06-26	2003-04-03	Statens Serum Institute	Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
CA2303908A1 (en) *	1997-09-18	1999-03-25	Gene Therapy Systems, Inc.	Chemical modification of dna using peptide nucleic acid conjugates
JP2002500190A (en) *	1998-01-08	2002-01-08	ザリージェンツオブザユニバーシティオブカリフォルニア	Kinesin motor modulators derived from marine sponges
US6927286B1 (en) *	1999-01-06	2005-08-09	The Regents Of The University Of California	Bleomycin gene cluster components and their uses
US6492103B1 (en) *	2000-01-31	2002-12-10	Organ Recovery Systems, Inc.	System for organ and tissue preservation and hypothermic blood substitution
EP1262180A4 (en) *	2000-02-18	2005-06-01	Takeda Pharmaceutical	TNF-ALPHA HEMMER
KR100426455B1 (en) *	2000-04-25	2004-04-13	김진우	Human cancer suppressor gene, protein encoding by same, expression vector containing same, and cell transformed by said vector
DE10031179A1 (en) *	2000-06-27	2002-01-31	Amaxa Gmbh	Introducing active molecules into the nucleus of eukaryotic cells, useful for transfection and gene therapy, by applying controlled electrical pulse
US7014990B2 (en) *	2000-10-13	2006-03-21	Ben O'Mar Arrington	Machine perfusion solution for organ and biological tissue preservation
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
DE10291734D2 (en)	2001-04-23	2004-05-27	Lorbach Elke	Buffer solution for electroporation and methods comprising using the same
US6562928B1 (en) *	2002-06-19	2003-05-13	Isp Investments Inc.	Terpolymer of maleic acid, maleic anhydride and alkylvinylether

2002
- 2002-04-23 DE DE10291734T patent/DE10291734D2/en not_active Expired - Fee Related
- 2002-04-23 US US10/475,967 patent/US7332332B2/en not_active Expired - Lifetime
- 2002-04-23 ES ES02740284T patent/ES2230502T3/en not_active Expired - Lifetime
- 2002-04-23 MX MXPA03009622A patent/MXPA03009622A/en unknown
- 2002-04-23 AU AU2002315658A patent/AU2002315658B2/en not_active Expired
- 2002-04-23 CN CNB028087046A patent/CN1302115C/en not_active Expired - Lifetime
- 2002-04-23 KR KR1020037013803A patent/KR100845057B1/en active IP Right Grant
- 2002-04-23 WO PCT/DE2002/001483 patent/WO2002086134A2/en active IP Right Grant
- 2002-04-23 CA CA2445260A patent/CA2445260C/en not_active Expired - Lifetime
- 2002-04-23 AT AT02740284T patent/ATE278796T1/en active
- 2002-04-23 DE DE50201240T patent/DE50201240D1/en not_active Expired - Lifetime
- 2002-04-23 IL IL15851402A patent/IL158514A0/en not_active IP Right Cessation
- 2002-04-23 EP EP02740284A patent/EP1390518B1/en not_active Expired - Lifetime
- 2002-04-23 JP JP2002583647A patent/JP4070611B2/en not_active Expired - Lifetime
2003
- 2003-10-20 NO NO20034682A patent/NO20034682L/en not_active Application Discontinuation
- 2003-10-20 ZA ZA200308127A patent/ZA200308127B/en unknown
2006
- 2006-11-09 US US11/595,448 patent/US8003389B2/en not_active Expired - Fee Related
2007
- 2007-10-31 US US11/931,996 patent/US8039259B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/931,886 patent/US20080145938A1/en not_active Abandoned
- 2007-12-28 KR KR1020070140428A patent/KR100879824B1/en active IP Right Grant
2011
- 2011-01-19 US US13/009,024 patent/US8192990B2/en not_active Expired - Fee Related

Publication	Publication Date	Title
AU2002315658A1 (en)	2003-04-17	Buffer solution for electroporation and a method comprising the use of the same
AU2002315095A1 (en)	2002-12-23	Electroporation microneedle and methods for its use
AU2002326600A1 (en)	2003-02-24	Side-exit catheter and method for its use
AU2002364528A1 (en)	2003-06-23	Bio-implant and method of making the same
AU2002324775A1 (en)	2003-03-10	Architecture tool and methods of use
AU2001245928A1 (en)	2001-11-26	Electrolyzer and method of using the same
AU2002361966A1 (en)	2003-06-17	Non-damaging fluid-loss control pill and method of using the same
AU2002360629A1 (en)	2003-06-30	Spray device and method
AU2002320456A1 (en)	2003-02-17	Removable stent and method of using the same
AU2002314466A1 (en)	2002-10-15	Withasol and methods of use
AUPR510001A0 (en)	2001-06-14	Formulation and method
AU2002362248A1 (en)	2003-03-24	Spray member and method for using the same
AU2001256373A1 (en)	2003-02-06	Syringe and method for the use thereof
AU2002245675A1 (en)	2002-09-24	Electromanipulation device and method
AU2001260774A1 (en)	2002-04-29	Bio-support and preparing method of the same
AU2002363938A1 (en)	2003-06-10	Methods and use of motoneuronotropic factors
EP1578723A3 (en)	2005-10-20	Process for the preparation of oxazolidinones and method of use thereof
AU2002367959A1 (en)	2003-12-31	Process for the preparation of oxazolidinones and method of use thereof
AU2002246049A1 (en)	2002-08-06	Water-absorbing agent, method for the production thereof and use of the same
AU2002234215A1 (en)	2002-07-16	Liquid colorant and method
AU2002341828A1 (en)	2003-04-01	Enhanced proteins and methods for their use
AU2002354363A1 (en)	2003-06-17	Method of activating protein
AUPR496501A0 (en)	2001-06-07	Method and device
AU2002320225A1 (en)	2003-01-21	Structural apparatus and method
WO2003016502A9 (en)	2010-01-28	Tramdorins and methods of using tramdorins